Cingulate (CINGW) Capital Expenditures (2021 - 2025)
Cingulate's (CINGW) quarterly Capital Expenditures came in at $156213.0 in Q4 2025, down 21.29% on a YoY basis from $198462.0 in Q4 2024, and down 21.29% quarter-over-quarter from $198462.0 in Q4 2024.
Analysis
Cingulate (CINGW) Capital Expenditures (2021 - 2025) Analysis & Trends
Cingulate (CINGW) has reported Capital Expenditures for 5 consecutive years, with $156213.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Capital Expenditures fell 21.29% year-over-year to $156213.0; the trailing twelve-month figure through Dec 2025 stood at $147643.0 (down 30.29% YoY), and the FY2025 full-year result was $162138.0, down 23.45% from the prior year.
- Capital Expenditures fell to $156213.0 in Q4 2025 per CINGW's latest filing, from $198462.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $710007.0 in Q4 2021 and bottomed at -$207032.0 in Q3 2024.
- Historically, Capital Expenditures has averaged $111447.5 across 5 years, with a median of $73988.5 in 2021.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures slumped 84.35% in 2022, then surged 13886100.0% in 2024.
- Over 5 years, Capital Expenditures stood at $710007.0 in 2021, then tumbled by 79.86% to $143020.0 in 2022, then jumped by 30.72% to $186960.0 in 2023, then gained by 6.15% to $198462.0 in 2024, then declined by 21.29% to $156213.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $156213.0, $198462.0, and -$207032.0 for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.46 Bn | 623.70 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 440.11 Bn | 433.54 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 365.04 Bn | 357.90 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | -321.00 Mn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 533.00 Mn |
| 6 | Sanofi | 52.47 Bn | 45.09 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.26 Bn | 44.26 Bn | - | 2.29 Mn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 12.41 Mn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | 108.00 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 156,213.00 |
| Dec 31, 2024 | 198,462.00 |
| Sep 30, 2024 | -207,032.00 |
| Jun 30, 2024 | 138,862.00 |
| Mar 31, 2024 | 81,508.00 |
| Dec 31, 2023 | 186,960.00 |
| Jun 30, 2023 | 1.00 |
| Mar 31, 2023 | 37,135.00 |
| Dec 31, 2022 | 143,020.00 |
| Mar 31, 2022 | 10,400.00 |
| Dec 31, 2021 | 710,007.00 |
| Sep 30, 2021 | 15,774.00 |
| Jun 30, 2021 | 22,486.00 |
| Mar 31, 2021 | 66,469.00 |